Efficiency of Rituximab for the treatment of the initial episode of steroid-sensitive nephrotic syndrome in children
10.3760/cma.j.cn101070-20240513-00292
- VernacularTitle:利妥昔单抗治疗儿童初发激素敏感型肾病综合征的疗效
- Author:
Tingting YUAN
1
;
Bingbing ZHU
1
;
Yan LI
1
;
Qianqian PENG
1
;
Huandan YANG
1
;
Na CHEN
1
;
Zhaowen ZHONG
1
;
Ruifeng ZHANG
1
Author Information
1. 徐州市儿童医院肾脏风湿免疫科，徐州 221006
- Publication Type:Journal Article
- Keywords:
Child;
Rituximab;
Initial episode nephrotic syndrome;
Steroid sensitive
- From:
Chinese Journal of Applied Clinical Pediatrics
2025;40(2):125-129
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of Rituximab (RTX) combined with short-term use of glucocorticoids in the treatment of the initial episode of steroid-sensitive nephrotic syndrome (SSNS).Methods:A retrospective case summary.A total of 30 children with SSNS treated in the Department of Intrarenal Rheumatism and Immunology, Xuzhou Children′s Hospital from December 2021 to March 2023, were enrolled in this study.They were given a standard dose of RTX (375 mg/m 2) and glucocorticoids for a short term.The patients were followed up for 1 year, and the general condition, changes in CD19 + B lymphocytes expression after RTX treatment, the relapse rate, the median relapse-free survival and adverse reactions of RTX were recorded.Kaplan-Meier method was used to analyze the relapse-free survival time. Results:CD19 + B lymphocytes were depleted 2 weeks after RTX treatment, and the median time required for CD19 + B lymphocytes reconstitution was 5 months after RTX treatment.The 1-year relapse-free rate was 90.00%, and the median relapse-free survival was 11 months.The glucocorticoid discontinuation rate was 93.33% in 3 months after RTX treatment, and 100% in 6 and 12 months after RTX treatment.Adverse reactions included infusion reactions in 7 cases (23.33%), neutropenia/leukopenia in 5 cases (16.67%), hypoimmunoglobulinemia in 10 cases (33.33%), infections in 4 cases.One case was complicated with severe influenza A virus infection after CD19 + B lymphocytes reconstruction. Conclusions:A standard dose of RTX can significantly reduce the relapse frequency, maintain long-term remission of proteinuria, and reduce the dose of glucocorticoids in patients at the initial episode of SSNS.Thus, it is worthy of clinical promotion.
